1 report

  • Synergys Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details

The company' s pipeline portfolio includes multifunctional antivasculogenic antibody fusion molecule for the treatment of triple negative breast cancer (TNBC); a therapeutic targeted for ovarian cancer and for HER##+ breast cancer; and a fully human bi-targeted antibody

  • Biotherapeutic
  • Cancer
  • United States
  • Deals & Alliance
  • Synergys Biotherapeutics, Inc.